O	0	1	[
O	1	10	Influence
O	11	13	of
B-intervention	14	27	dexamethasone
O	28	30	on
O	31	34	the
B-condition	35	44	incidence
I-condition	45	47	of
I-condition	48	61	postoperative
I-condition	62	68	nausea
I-condition	69	72	and
I-condition	73	81	vomiting
O	82	84	in
B-eligibility	85	91	breast
I-eligibility	92	98	cancer
I-eligibility	99	107	patients
I-eligibility	108	112	with
I-eligibility	113	124	neoadjuvant
I-eligibility	125	137	chemotherapy
O	137	138	]
O	138	139	.

O	140	142	To
O	143	151	evaluate
O	152	155	the
O	156	165	influence
O	166	168	of
O	169	182	dexamethasone
O	183	185	on
O	186	189	the
O	190	199	incidence
O	200	202	of
O	203	216	postoperative
O	217	223	nausea
O	224	227	and
O	228	236	vomiting
O	237	238	(
O	238	242	PONV
O	242	243	)
O	244	246	in
O	247	255	patients
O	256	266	undergoing
O	267	275	modified
O	276	283	radical
O	284	294	mastectomy
O	295	299	with
O	300	311	neoadjuvant
O	312	324	chemotherapy
O	324	325	.

O	326	328	In
O	329	330	a
O	331	342	prospective
O	343	348	trial
O	348	349	,
B-total-participants	350	353	280
O	354	360	female
O	361	362	(
B-age	362	364	18
I-age	364	365	-
I-age	365	367	60
I-age	368	373	years
O	373	374	)
B-eligibility	375	381	breast
I-eligibility	382	388	cancer
I-eligibility	389	397	patients
I-eligibility	398	408	undergoing
I-eligibility	409	417	modified
I-eligibility	418	425	radical
I-eligibility	426	436	mastectomy
I-eligibility	437	441	with
I-eligibility	442	453	neoadjuvent
I-eligibility	454	466	chemotherapy
O	467	471	were
O	472	482	randomized
O	483	485	to
O	486	489	two
O	490	496	groups
O	496	497	:
O	498	501	one
O	502	506	with
O	507	520	dexamethasone
O	521	522	(
O	522	527	Group
O	528	529	D
O	529	530	)
O	531	534	and
O	535	538	one
B-control	539	546	without
I-control	547	560	dexamethasone
O	561	562	(
O	562	567	Group
O	568	569	C
O	569	570	,
O	571	572	n
O	572	573	=
B-control-participants	573	576	140
O	576	577	)
O	577	578	.

O	579	581	In
O	582	586	each
O	587	592	group
O	592	593	,
O	594	604	anesthesia
O	605	608	was
O	609	619	maintained
O	620	624	with
O	625	633	volatile
O	634	644	anesthesia
O	645	647	or
O	648	653	total
O	654	665	intravenous
O	666	676	anesthesia
O	677	678	(
O	678	682	TIVA
O	682	683	)
O	683	684	:
O	685	689	TIVA
O	690	691	(
O	691	699	propofol
O	699	700	)
O	701	708	without
O	709	722	dexamethasone
O	723	724	(
O	724	732	Subgroup
O	733	735	CP
O	735	736	)
O	736	737	;
O	738	746	volatile
O	747	757	anesthesia
O	758	759	(
O	759	770	sevoflurane
O	770	771	)
O	772	779	without
O	780	793	dexamethasone
O	794	795	(
O	795	803	Subgroup
O	804	806	CS
O	806	807	)
O	807	808	;
O	809	813	TIVA
O	814	818	with
O	819	821	10
O	822	824	mg
O	825	838	dexamethasone
O	839	852	intravenously
O	853	859	before
O	860	870	anesthetic
O	871	880	induction
O	881	882	(
O	882	890	Subgroup
O	891	893	DP
O	893	894	)
O	894	895	;
O	896	904	volatile
O	905	915	anesthesia
O	916	920	with
O	921	923	10
O	924	926	mg
O	927	940	dexamethasone
O	941	954	intravenously
O	955	961	before
O	962	972	anesthetic
O	973	982	induction
O	983	984	(
O	984	992	Subgroup
O	993	995	DS
O	995	996	)
O	996	997	.

O	998	999	A
O	1000	1008	standard
O	1009	1016	general
O	1017	1027	anesthetic
O	1028	1037	technique
O	1038	1041	was
O	1042	1046	used
O	1046	1047	.

O	1048	1051	All
O	1052	1055	the
O	1056	1064	patients
O	1065	1073	received
O	1074	1075	8
O	1076	1078	mg
O	1079	1081	of
O	1082	1093	ondansetron
O	1094	1107	intravenously
O	1108	1110	30
O	1111	1118	minutes
O	1119	1125	before
O	1126	1129	the
O	1130	1133	end
O	1134	1136	of
O	1137	1145	surgical
O	1146	1156	procedures
O	1156	1157	.

O	1158	1161	The
O	1162	1171	incidence
O	1172	1174	of
O	1175	1179	PONV
O	1180	1186	during
O	1187	1190	the
O	1191	1193	24
O	1193	1194	-
O	1194	1198	hour
O	1199	1212	postoperative
O	1213	1219	period
O	1220	1223	was
O	1224	1232	recorded
O	1232	1233	.

O	1234	1235	A
O	1236	1244	Logistic
O	1245	1255	regression
O	1256	1264	analysis
O	1265	1268	was
O	1269	1278	conducted
O	1279	1281	to
O	1282	1289	examine
O	1290	1298	relevant
O	1299	1306	factors
O	1307	1310	for
O	1311	1315	PONV
O	1315	1316	.

O	1317	1320	The
O	1321	1327	tested
O	1328	1335	factors
O	1336	1340	were
O	1340	1341	:
O	1342	1345	age
O	1345	1346	,
O	1347	1351	body
O	1352	1356	mass
O	1357	1362	index
O	1363	1364	(
O	1364	1367	BMI
O	1367	1368	)
O	1368	1369	,
O	1370	1378	duration
O	1379	1381	of
O	1382	1389	surgery
O	1389	1390	,
O	1391	1404	postoperative
O	1405	1409	pain
O	1409	1410	,
O	1411	1418	history
O	1419	1421	of
O	1422	1428	motion
O	1429	1437	sickness
O	1437	1438	/
O	1438	1442	PONV
O	1442	1443	,
O	1444	1448	with
O	1449	1451	or
O	1452	1459	without
O	1460	1473	dexamethasone
O	1474	1477	and
O	1478	1488	anesthetic
O	1489	1496	regimen
O	1496	1497	.

O	1498	1503	There
O	1504	1507	was
O	1508	1509	a
O	1510	1521	significant
O	1522	1527	lower
B-outcome	1528	1537	incidence
I-outcome	1538	1540	of
I-outcome	1541	1545	PONV
O	1546	1548	in
O	1549	1552	the
O	1553	1561	patients
O	1562	1565	who
O	1566	1574	received
O	1575	1588	dexamethasone
O	1589	1593	than
O	1594	1596	in
O	1597	1602	those
O	1603	1606	who
O	1607	1615	received
O	1616	1623	placebo
O	1624	1630	during
O	1631	1634	the
B-outcome	1635	1637	24
I-outcome	1637	1638	-
I-outcome	1638	1642	hour
I-outcome	1643	1656	postoperative
I-outcome	1657	1663	period
O	1664	1665	(
B-iv-bin-percent	1665	1667	11
I-iv-bin-percent	1667	1668	.
I-iv-bin-percent	1668	1669	4
I-iv-bin-percent	1669	1670	%
O	1671	1673	vs
O	1673	1674	.
B-cv-bin-percent	1675	1677	20
I-cv-bin-percent	1677	1678	.
I-cv-bin-percent	1678	1679	7
I-cv-bin-percent	1679	1680	%
O	1680	1681	,
O	1682	1683	P
O	1683	1684	=
O	1684	1685	0
O	1685	1686	.
O	1686	1689	034
O	1689	1690	)
O	1690	1691	.

O	1692	1694	In
O	1695	1698	the
B-outcome	1699	1704	early
I-outcome	1705	1718	postoperative
I-outcome	1719	1725	period
I-outcome	1726	1727	(
I-outcome	1727	1728	0
I-outcome	1728	1729	-
I-outcome	1729	1730	2
I-outcome	1731	1732	h
I-outcome	1732	1733	)
O	1734	1747	dexamethasone
O	1748	1755	reduced
O	1756	1759	the
B-outcome	1760	1769	incidence
I-outcome	1770	1772	of
I-outcome	1773	1777	PONV
O	1778	1779	(
B-iv-bin-percent	1780	1781	1
I-iv-bin-percent	1781	1782	.
I-iv-bin-percent	1782	1783	4
I-iv-bin-percent	1783	1784	%
O	1784	1786	vs
O	1786	1787	.
B-cv-bin-percent	1787	1788	6
I-cv-bin-percent	1788	1789	.
I-cv-bin-percent	1789	1790	4
I-cv-bin-percent	1790	1791	%
O	1791	1792	,
O	1793	1794	P
O	1794	1795	=
O	1795	1796	0
O	1796	1797	.
O	1797	1800	031
O	1800	1801	)
O	1801	1802	,
O	1803	1806	but
O	1807	1809	in
O	1810	1813	the
B-outcome	1814	1818	late
I-outcome	1819	1832	postoperative
I-outcome	1833	1839	period
I-outcome	1840	1841	(
I-outcome	1841	1842	2
I-outcome	1842	1843	-
I-outcome	1843	1845	24
I-outcome	1846	1847	h
I-outcome	1847	1848	)
O	1849	1852	the
O	1853	1863	difference
O	1864	1866	of
O	1867	1870	the
O	1871	1880	incidence
O	1881	1884	was
O	1885	1900	insignificantly
O	1901	1902	(
B-iv-bin-percent	1902	1904	10
I-iv-bin-percent	1904	1905	.
I-iv-bin-percent	1905	1906	7
I-iv-bin-percent	1906	1907	%
O	1908	1910	vs
O	1910	1911	.
B-cv-bin-percent	1912	1914	17
I-cv-bin-percent	1914	1915	.
I-cv-bin-percent	1915	1916	9
I-cv-bin-percent	1916	1917	%
O	1917	1918	,
O	1919	1920	P
O	1920	1921	=
O	1921	1922	0
O	1922	1923	.
O	1923	1926	088
O	1926	1927	)
O	1927	1928	.

O	1929	1931	No
O	1932	1943	differences
O	1944	1948	were
O	1949	1954	found
O	1955	1962	between
B-outcome	1963	1967	TIVA
I-outcome	1968	1971	and
I-outcome	1972	1980	volatile
I-outcome	1981	1991	anesthesia
O	1992	1994	in
O	1995	1998	the
O	1999	2001	24
O	2001	2002	-
O	2002	2006	hour
O	2007	2020	postoperative
O	2021	2027	period
O	2027	2028	.

O	2029	2042	Dexamethasone
O	2043	2046	was
O	2047	2056	effective
O	2057	2059	to
O	2060	2067	prevent
O	2068	2072	PONV
O	2072	2073	(
O	2073	2075	OR
O	2075	2076	=
O	2076	2077	0
O	2077	2078	.
O	2078	2081	447
O	2081	2082	,
O	2083	2084	P
O	2084	2085	=
O	2085	2086	0
O	2086	2087	.
O	2087	2090	030
O	2090	2091	)
O	2091	2092	,
O	2093	2096	and
O	2097	2104	history
O	2105	2107	of
O	2108	2112	PONV
O	2113	2115	or
O	2116	2122	motion
O	2123	2131	sickness
O	2132	2135	was
O	2136	2139	the
O	2140	2144	risk
O	2145	2151	factor
O	2152	2154	of
O	2155	2159	PONV
O	2160	2161	(
O	2161	2163	OR
O	2163	2164	=
O	2164	2166	15
O	2166	2167	.
O	2167	2170	730
O	2170	2171	,
O	2172	2173	P
O	2173	2174	<
O	2174	2175	0
O	2175	2176	.
O	2176	2179	001
O	2179	2180	)
O	2180	2181	.

O	2182	2195	Dexamethasone
O	2196	2204	prevents
O	2205	2209	PONV
O	2210	2221	effectively
O	2222	2224	in
O	2225	2233	patients
O	2234	2244	undergoing
O	2245	2253	modified
O	2254	2261	radical
O	2262	2272	mastectomy
O	2273	2277	with
O	2278	2289	neoadjuvant
O	2290	2302	chemotherapy
O	2302	2303	,
O	2304	2307	and
O	2308	2312	TIVA
O	2313	2319	cannot
O	2320	2328	decrease
O	2329	2332	the
O	2333	2342	incidence
O	2343	2345	of
O	2346	2350	PONV
O	2351	2353	in
O	2354	2357	the
O	2358	2360	24
O	2360	2361	-
O	2361	2365	hour
O	2366	2379	postoperative
O	2380	2386	period
O	2387	2389	in
O	2390	2395	those
O	2396	2404	patients
O	2404	2405	.
